Table 3
Open in new tab

Study endpoints

Limited ablation groupExtended ablation groupP
n = 38n = 36
Primary endpoint
 – Documented arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period17 (45%)15 (42%)NS
Secondary endpoints
 – Documented on-drug arrhythmia recurrence10 (26%)7 (19%)NS
 – Symptoms of arrhythmia13 (34%)10 (28%)NS
 – Patients with emergency visits/number of emergency visits per patient11 (29%)/2 (1; 3)9 (25%)/2 (1; 2)NS/NS
 – Patients with hospitalization/number of hospitalizations per patient14 (37%)/1 (1; 2)13 (36%)/2 (1; 2)NS/NS
 – Patients with cardiovascular emergency visits or hospitalization/number of events per patient13 (24%)/1 (1; 3)11 (31%)/1 (1; 2)NS/NS
 – Mortality9 (24%)10 (28%)NS
 – Antiarrhythmic drugs (post-blanking period)16 (42%)7 (19%)0.046
 – Antiarrhythmic drugs (at the end of follow-up)11 (29%)7 (19%)NS
 – Reablation rate5 (13%)3 (8%)NS
 – Pacemaker implantation3 (8%)1 (3%)NS
 – AV junction ablation01 (3%)NS
Other objectives (12-month visit—baseline difference)
 – 6-minute walking test (m)−10 (−27; 55)9 (−28; 163)NS
 – EQ-VAS−4 (−12; 14)0 (−18; 22)NS
 – NT-proBNP (pg/mL)239 (−312; 1120)98 (−512; 695)NS
Major procedural complications5 (13%)4 (11%)NS
Limited ablation groupExtended ablation groupP
n = 38n = 36
Primary endpoint
 – Documented arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period17 (45%)15 (42%)NS
Secondary endpoints
 – Documented on-drug arrhythmia recurrence10 (26%)7 (19%)NS
 – Symptoms of arrhythmia13 (34%)10 (28%)NS
 – Patients with emergency visits/number of emergency visits per patient11 (29%)/2 (1; 3)9 (25%)/2 (1; 2)NS/NS
 – Patients with hospitalization/number of hospitalizations per patient14 (37%)/1 (1; 2)13 (36%)/2 (1; 2)NS/NS
 – Patients with cardiovascular emergency visits or hospitalization/number of events per patient13 (24%)/1 (1; 3)11 (31%)/1 (1; 2)NS/NS
 – Mortality9 (24%)10 (28%)NS
 – Antiarrhythmic drugs (post-blanking period)16 (42%)7 (19%)0.046
 – Antiarrhythmic drugs (at the end of follow-up)11 (29%)7 (19%)NS
 – Reablation rate5 (13%)3 (8%)NS
 – Pacemaker implantation3 (8%)1 (3%)NS
 – AV junction ablation01 (3%)NS
Other objectives (12-month visit—baseline difference)
 – 6-minute walking test (m)−10 (−27; 55)9 (−28; 163)NS
 – EQ-VAS−4 (−12; 14)0 (−18; 22)NS
 – NT-proBNP (pg/mL)239 (−312; 1120)98 (−512; 695)NS
Major procedural complications5 (13%)4 (11%)NS

Data represent the number of cases (percentage) or median (interquartile range).

Details on major procedural complications are provided in Supplementary material online, Table S3.

EQ-VAS, European Quality of Life Group instrument self-report questionnaire visual analogue scale; NS, not significant.

Table 3
Open in new tab

Study endpoints

Limited ablation groupExtended ablation groupP
n = 38n = 36
Primary endpoint
 – Documented arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period17 (45%)15 (42%)NS
Secondary endpoints
 – Documented on-drug arrhythmia recurrence10 (26%)7 (19%)NS
 – Symptoms of arrhythmia13 (34%)10 (28%)NS
 – Patients with emergency visits/number of emergency visits per patient11 (29%)/2 (1; 3)9 (25%)/2 (1; 2)NS/NS
 – Patients with hospitalization/number of hospitalizations per patient14 (37%)/1 (1; 2)13 (36%)/2 (1; 2)NS/NS
 – Patients with cardiovascular emergency visits or hospitalization/number of events per patient13 (24%)/1 (1; 3)11 (31%)/1 (1; 2)NS/NS
 – Mortality9 (24%)10 (28%)NS
 – Antiarrhythmic drugs (post-blanking period)16 (42%)7 (19%)0.046
 – Antiarrhythmic drugs (at the end of follow-up)11 (29%)7 (19%)NS
 – Reablation rate5 (13%)3 (8%)NS
 – Pacemaker implantation3 (8%)1 (3%)NS
 – AV junction ablation01 (3%)NS
Other objectives (12-month visit—baseline difference)
 – 6-minute walking test (m)−10 (−27; 55)9 (−28; 163)NS
 – EQ-VAS−4 (−12; 14)0 (−18; 22)NS
 – NT-proBNP (pg/mL)239 (−312; 1120)98 (−512; 695)NS
Major procedural complications5 (13%)4 (11%)NS
Limited ablation groupExtended ablation groupP
n = 38n = 36
Primary endpoint
 – Documented arrhythmia recurrence >30 s without antiarrhythmic drugs after the 3-month blanking period17 (45%)15 (42%)NS
Secondary endpoints
 – Documented on-drug arrhythmia recurrence10 (26%)7 (19%)NS
 – Symptoms of arrhythmia13 (34%)10 (28%)NS
 – Patients with emergency visits/number of emergency visits per patient11 (29%)/2 (1; 3)9 (25%)/2 (1; 2)NS/NS
 – Patients with hospitalization/number of hospitalizations per patient14 (37%)/1 (1; 2)13 (36%)/2 (1; 2)NS/NS
 – Patients with cardiovascular emergency visits or hospitalization/number of events per patient13 (24%)/1 (1; 3)11 (31%)/1 (1; 2)NS/NS
 – Mortality9 (24%)10 (28%)NS
 – Antiarrhythmic drugs (post-blanking period)16 (42%)7 (19%)0.046
 – Antiarrhythmic drugs (at the end of follow-up)11 (29%)7 (19%)NS
 – Reablation rate5 (13%)3 (8%)NS
 – Pacemaker implantation3 (8%)1 (3%)NS
 – AV junction ablation01 (3%)NS
Other objectives (12-month visit—baseline difference)
 – 6-minute walking test (m)−10 (−27; 55)9 (−28; 163)NS
 – EQ-VAS−4 (−12; 14)0 (−18; 22)NS
 – NT-proBNP (pg/mL)239 (−312; 1120)98 (−512; 695)NS
Major procedural complications5 (13%)4 (11%)NS

Data represent the number of cases (percentage) or median (interquartile range).

Details on major procedural complications are provided in Supplementary material online, Table S3.

EQ-VAS, European Quality of Life Group instrument self-report questionnaire visual analogue scale; NS, not significant.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close